Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Biomedical Advanced Research and Development Authority Stories

2013-05-15 16:26:57

Design Enables More Rapid Response to Potential Pandemics LA JOLLA, Calif. and ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- A team of international researchers from the J. Craig Venter Institute (JCVI), Synthetic Genomics Inc. (SGI), Novartis Vaccines and Diagnostics, the Biomedical Advanced Research and Development Authority (BARDA, US Department of Health and Human Services), and Institut fur Virologie, Phillips Universitat, has published a study detailing new methods to rapidly...

2013-05-03 08:25:23

PRINCETON, N.J., May 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today its financial results for the quarter ended March 31, 2013. Soligenix's revenues for the quarter ended March 31, 2013 were $0.9 million as compared to $0.6 million for the first quarter of 2012....

2013-05-01 08:30:52

Soligenix to Expand Biodefense and Infectious Disease Product Pipeline PRINCETON, N.J. and GERMANTOWN, Md., May 1, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today it will jointly develop a treatment for Melioidosis through a worldwide exclusive collaboration with Intrexon, a synthetic...

2013-04-16 08:28:30

Presentation on April 18, 2013 PRINCETON, N.J., April 16, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products for serious inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that its Chief Scientific Officer, Robert N. Brey, PhD, will give a presentation on the stockpiling of biodefense vaccines - technology...

2013-03-26 12:29:23

Team will develop and manufacture GSK's next generation influenza vaccines to protect the nation against global pandemics AUSTIN, Texas and PHILADELPHIA, March 26, 2013 /PRNewswire/ -- GlaxoSmithKline plc (GSK) and The Texas A&M University System announced today that the U.S. Department of Health and Human Services (DHHS) has approved the establishment of a $91 million influenza-vaccines manufacturing facility as the anchor of the Center for Innovation in Advanced Development and...

2013-02-28 16:27:49

$44 Million Contract with U.S. Department of Health and Human Services to Fund Completion of Clinical Development and Preparation for Submission of New Drug Application for NT-300 TAMPA, Fla., Feb. 28, 2013 /PRNewswire/ -- Romark Laboratories has been awarded a contract with the U.S. Department of Health and Human Services (HHS) to complete the advanced development of NT-300 (nitazoxanide) as a treatment of acute uncomplicated influenza. The value of the cost plus fixed-fee contract...

2013-02-26 08:28:26

PRINCETON, N.J., Feb. 26, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the year ended December 31, 2012. Soligenix's revenues for the year ended December 31, 2012 were $3.1 million as compared to $7.6 million for the prior year. The decrease in revenues was a result of $5.0 million received in 2011 from Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) for rights to...

2013-02-20 08:28:05

PRINCETON, N.J., Feb. 20, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today submission of a full contract proposal to the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures. This submission supports a potential multi-year, multi-million dollar contract to develop OrbeShield(TM) (oral beclomethasone...

2013-02-15 16:23:21

PEARL RIVER, N.Y., Feb. 15, 2013 /PRNewswire/ -- At a press conference today showcasing Protein Sciences' newly leased manufacturing facility for Flublok, the Company announced that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, will continue to support the Company's influenza vaccines program. BARDA held an internal review of the Protein Sciences program and made a decision to modify its contract with the...

2013-01-07 08:28:28

PRINCETON, N.J., Jan. 7, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that pursuant to review of the Company's white paper on development of OrbeShield(TM) as a countermeasure for the gastrointestinal effects of acute radiation syndrome (GI ARS), the Biomedical Advanced Research and Development Authority (BARDA), Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical...